Abstract 681TiP
Background
AMXI-5001 is a novel, first-in-class, orally bioavailable dual-action PARP/microtubule small-molecule inhibitor. It has shown anti-tumor activity in multiple preclinical models. This study is an open-label, multi-center, non-randomized dose escalation study of AMXI-5001 as monotherapy in patients with refractory advanced malignancies with a dose expansion in patients with HRD mutations.
Trial design
AMXI-5001 is administered orally twice daily (BID) on a continuous 7-day dosing regimen in the dose escalation phase. The primary endpoints are assessing safety, tolerability, pharmacokinetics (PK), determining the maximum tolerated dose (MTD), and recommended Phase2 dose (RP2D). The secondary endpoint is preliminary efficacy. The dose-limiting toxicity (DLT) will be assessed during Cycle 1 treatment. Once the RP2D is defined, the trial will advance into two phase 2 expansion basket cohorts: Cohort 1 will include patients with Homologous recombination deficiency (HRD) mutations with no prior PARP inhibitor treatment. Cohort 2 will include BRCA1 and BRCA2 mutated patients who progressed on prior PARP inhibitors. The dose expansion phase's primary endpoint is the preliminary efficacy. The secondary endpoint is to characterize the safety and tolerability further.
Clinical trial identification
NCT04503265, ATLAS-101.
Editorial acknowledgement
We acknowledge Clinical Resource Solutions staff for their assistance in the development of this abstract.
Legal entity responsible for the study
AtlasMedx, Incorporated.
Funding
AtlasMedx, Incorporated.
Disclosure
R. Costa: Other, Personal, Speaker, Consultant, Advisor, Honoraria: Pfizer, Daiichi Sankyo, Astra Zenaka, Athenex Oncology; Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Gilead. H. Alaoui: Financial Interests, Personal and Institutional, Officer, stock ownership: AtlasMedx,Inc. D.M. Jablons: Financial Interests, Personal, Advisory Board: AtlasMedx,Inc. P. Munster: Financial Interests, Personal, Advisory Role: AtlasMedx,Inc. All other authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01